Skip to main content
Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study

Fig. 1

Absolute and relative risk reduction (ARR and RRR) in the incidence of a 3-point major adverse cardiovascular event (3P-MACE) in cardiovascular outcome trials with SGLT-2 inhibitor (SGLT-2i) or GLP-1 receptor agonist (GLP-1RA). The diamond indicates the pooled estimates, and the boxes are each study with 95% confidence interval. (A) Absolute risk reduction in the incidence of 3P-MACE by SGLT-2i and GLP-1RA. (B) Relative risk reduction in the incidence of 3P-MACE by SGLT-2i and GLP-1RA

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840